Drug
Chiauranib clinical trials
Also written CS2164.
Keep track of what changes. Save the chiauranib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
15 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 3 |
| 2022 | 4 |
| 2024 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 15 · Other 0
Often tested with
Tested in the same studies.
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses chiauranib is read from its arms, and is right about nine times in ten.
Testing it · 15
- Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal AdenocarcinomaNot yet recruitingPhase 3Chipscreen Biosciences, Ltd.NCT07445295Written as Chiauranib
- Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian CancerRecruitingPhase 3Chipscreen Biosciences, Ltd.NCT04921527Written as chiauranib
- Chiauranib for Advanced Solid Malignant Tumors and Relapsed/Refractory SCLC.RecruitingPhase 1/2Chipscreen Biosciences, Ltd.NCT05271292Written as Chiauranib
- Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal AdenocarcinomaActive, not recruitingPhase 2Chipscreen Biosciences, Ltd.NCT06492915Written as Chiauranib
- Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS)CompletedPhase 2Chipscreen Biosciences, Ltd.NCT05497843Written as Chiauranib
- A Phase II Study of Chiauranib in Combine With Capecitabine in TNBCTerminatedPhase 2Chipscreen Biosciences, Ltd.NCT05336721Written as Chiauranib
- Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung CancerCompletedPhase 3Chipscreen Biosciences, Ltd.NCT04830813Written as Chiauranib
- Mass Balance Study of [14C]ChiauranibCompletedNot applicableChipscreen Biosciences, Ltd.NCT05371899Written as Chiauranib
- Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung CancerCompletedPhase 1Chipscreen Biosciences, Ltd.NCT03216343Written as Chiauranib
- Trial of Chiauranib Capsule on Pharmacokinetics to Assess the Effect of High Fat Diet in Healthy VolunteersCompletedPhase 1Chipscreen Biosciences, Ltd.NCT05346601Written as Chiauranib
- Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's LymphomaCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03974243Written as Chiauranib
- Study of Chiauranib in Patients With Advanced Hepatocellular CarcinomaCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03245190Written as Chiauranib
- Phase Ib Study of Chiauranib in Patients With Ovarian CancerCompletedPhase 1/2Chipscreen Biosciences, Ltd.NCT03166891Written as Chiauranib
- Study of Chiauranib in Relapsed/Refractory Non-Hodgkin's LymphomaTerminatedPhase 1Chipscreen Biosciences, Ltd.NCT03074825Written as Chiauranib
- Phase I Study of Chiauranib in Patients With Advanced Solid TumorsCompletedPhase 1Chipscreen Biosciences, Ltd.NCT02122809Written as Chiauranib
Given in every arm · 1 — chiauranib is usual care beside what is tested
Codes
What other systems call chiauranib · ClinicalTrials.gg INT001282
- MeSH (NLM) C000705608chiauranibConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) F40IRN5981IBCASERTIBConfirmed FDA, NLM
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000705608 | chiauranib | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | F40IRN5981 | IBCASERTIB | Confirmed FDA, NLM |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.